Declining kidney function predicts increasing cardiovascular risk in people with hypertension. Microalbuminuria is a marker for cardiovascular risk and declining kidney function. Agents that block the renin-angiotensin-aldosterone system (RAAS), notably angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs), reduce proteinuria and microalbuminuria, lower blood pressure and slow the progression of proteinuric kidney disease. Evidence is accumulating that the combination of an ACE inhibitor and an ARB is the optimal means of RAAS blockade in this setting, slowing the progression of nephropathy independently of blood pressure lowering to a greater degree than can be achieved using maximum approved doses of either agent alone. However, the emerging therapeutic potential of ACE inhibitor/ARB combination therapy in hypertensive kidney disease requires further characterization. The Irbesartan in the Management of PROteinuric patients at high risk for Vascular Events trial aims to determine definitively whether the combination therapy of an ARB, irbesartan and an ACE inhibitor, ramipril, is more effective than ramipril alone in reducing the urinary albumin excretion rate in patients at high cardiovascular risk with hypertension and proteinuria or microalbuminuria.
Introduction
Loss of kidney function is an independent predictor of cardiovascular risk in people with hypertension, and the higher a patient's global cardiovascular risk, the greater the likelihood that kidney dysfunction will be present. [1] [2] [3] [4] [5] [6] In particular, the presence of micro-or macroalbuminuria or a confirmed value of estimated glomerular filtration rate or creatinine clearance below 60 ml/min identifies hypertensive patients as having an additional cardiovascular risk. 7, 8 Frequently, these alterations co-exist with a third risk factor, left ventricular hypertrophy, which further increases cardiovascular risk. [9] [10] [11] A post hoc analysis of the HOPE study demonstrated that increases in serum creatinine and albuminuria are associated with increased cardiovascular risk, particularly in patients who already have a significant increase in global cardiovascular risk owing to the presence of diabetes with other associated risk factors and/or established cardiovascular disease. 12 However, when kidney disease in hypertensive patients is effectively treated, outcomes improve: post hoc analyses of both HOPE and the LIFE study showed that a reduction of urinary albumin excretion levels was correlated with a decrease in the number of cardiovascular events and death. 12, 13 As summarized in Table 1 , the ability of reninangiotensin-aldosterone system (RAAS)-blocking interventions to slow progression of advanced kidney disease in hypertensive patients with proteinuria is well established. 14 Moreover, in post hoc analyses of three separate studies, the magnitude of change in proteinuria at 6 months determined renal outcome at 3-5 years; an effect that could not be explained by changes in blood pressure alone. [15] [16] [17] Thus, guidelines recommend agents that block the RAAS be part of an antihypertensive regimen in chronic kidney disease patients to not only lower blood pressure but reduce proteinuria. 7, 8 Whereas proteinuria (i.e. macroalbuminuria) defined as 4300 mg/day of protein in the urine or a urinary albumin excretion rate (UAER) of 4200 mg/ min is a hallmark of established kidney disease, microalbuminuria (30-300 mg/day of protein in the urine or an UAER of 20-200 mg/min) is associated with increased cardiovascular risk and, in many cases if not reduced will progress to overt kidney disease. 18, 19 Indeed, the association between albuminuria and cardiovascular risk is a continuous one and even lower levels of albuminuria are associated with an elevated risk. 20 Aggressive blood pressure control is an important component of albuminuria reduction in microalbuminuric patients, but RAAS blockade once again reduces microalbuminuria to a greater degree than can be accounted for by effects on blood pressure reductions. 21 The angiotensin receptor blocker (ARB) irbesartan and the angiotensin-converting enzyme (ACE) inhibitor ramipril have both been shown to reduce microalbuminuria more effectively than non-RAAS-targeted antihypertensives in high-risk patients. 22, 23 Currently, it is unclear whether the combination of an ACE inhibitor with an ARB, provides greater renoprotection than the use of either approach alone. 24 The COOPERATE trial combined an ACE inhibitor and an ARB and demonstrated an additional 30% reduction in proteinuria over either agent alone, an effect independent of blood pressure. 25, 26 This implies an additive effect of these agents that is specific to the intrarenal RAAS. 26 However, further data are required to characterize the relative merits of single and combined RAAS blockade in hypertension patients with kidney dysfunction and lower levels of albuminuria, particularly focusing on patients with microalbuminuria.
The IMPROVE trial
The IMPROVE (Irbesartan in the Management of PROteinuric patients at high risk for Vascular Events) trial is designed to address the issue of combined RAAS blockade with ARBs and ACE inhibitors in patients with albuminuria. The trial compares ACE inhibitor therapy using ramipril with the ACE inhibitor/ARB combination of ramipril and irbesartan. Both proteinuric and microalbuminuric patients are included within the study population, permitting combination therapy to be assessed across a broad spectrum of baseline renal and cardiovascular risk. The active treatment phase of the trial has recently been completed and the baseline characteristics of 407 patients recruited are currently being analysed. We describe here the design and objectives of the study.
Materials and methods

Patients
Patients eligible for inclusion were men and women aged 55 years and older with a documented history of hypertension (4140/90 mm Hg) and albuminuria. To be eligible for randomization into the active treatment phase, subjects had to have a confirmed AER of 20-700 mg/min in two consecutive overnight urine collections before randomization and a systolic blood pressure 150 mm Hg and/or a diastolic blood pressure 95 mm Hg. Subjects were required to have been receiving treatment with an ACE inhibitor, at a dose equivalent to 5 mg or more of ramipril, for a minimum of 2 months before screening. Selection criteria are listed in Table 2 .
Study design
The IMPROVE trial is a multicentre, randomized, double-blind, placebo-controlled, parallel group study, in which hypertensive subjects with albuminuria plus additional indicators of increased cardiovascular risk were assigned to ramipril 10 mg plus placebo, or ramipril 10 mg plus irbesartan 150-300 mg, for 20 weeks. Institutional and ethical review board approval for the study protocol was granted at all participating centres, and all participants were required to give written informed consent before entry into the study.
The study design is summarized in Figure 1 . At the screening/enrollment visit, the physician called the Interactive Voice Response System (IVRS) to enroll the patients and sequentially assign, across all sites, a unique subject number. Screening was followed by a placebo lead-in phase of 14 days, then an active treatment phase of 20 weeks. During the placebo run-in period, subjects were required to discontinue or taper their previous ACE inhibitor and other antihypertensive medications and begin receiving placebo tablets once daily. At week 0, eligible subjects were randomized to one of two treatment arms (irbesartan or matching placebo) in a 1:1 ratio by IVRS. The IVRS was available 24 h per day and 7 days a week. The evaluation and visit schedules for the placebo run-in and active treatment phases are shown in Table 3 . The relatively long, 20-week duration of active treatment was based on the observation in the COOPERATE study that the response in the mono-and dual therapy treatment arms continued to diverge over approximately 5 months. 25 The primary objective of the IMPROVE study is to compare from baseline the change in albumin excretion rate (AER) between the ramipril and 38 Abbreviations: ABPM, ambulatory blood pressure monitoring; ACR, albumin:creatinine ratio; BP, blood pressure; CV, cardiovascular; DM, diabetes mellitus; ESRD, end stage renal disease; GFR, glomerular filtration rate; LVH, left ventricular hypertrophy; MAU, microalbuminuria; PU, proteinuria; UAER, urinary albumin excretion rate; UPCR, urine protein/creatinine ratio. ramipril/irbesartan arms after 20 weeks of active treatment. Secondary objectives are to compare the change from baseline in seated systolic and diastolic blood pressures within and between treatment groups, and to characterize the safety profile of each of the two treatment strategies.
Two subgroup analyses will be conducted with respect to the primary efficacy variable. One will conduct separate analyses of the response in microalbuminuric subjects (AERo200 mg/min) and overt nephropathic subjects (AER4200 mg/min). The second will conduct separate analyses for subgroups defined by the presence or absence of type II diabetes.
Active treatment phase
All subjects began active treatment on ramipril 5 mg, which was increased to 10 mg after 1 week. At this point, patients were also randomized to receive either irbesartan or matching placebo on a 1:1 ratio in a double-blind fashion ( Table 2 , active treatment randomization criteria). Also at week 0, all patients began taking 2 weeks of dummy placebo to allow the safe titration to target ramipril dose. Irbesartan was initiated at 150 mg once daily at week 2 for 2 weeks and then titrated to irbesartan 300 mg for the remaining 16 weeks of the study. Those unable to tolerate titration to maximal dose irbesartan or matching placebo were allowed to have their dosage tapered to the lower dose of irbesartan.
Throughout the active treatment phase, patients in both arms were set a target blood pressure of o130/80 mm Hg. Clinicians were free to use any antihypertensive drugs other than ACE inhibitors or ARBs to achieve and sustain these goals for their patients. Active treatment randomization criteria Subjects who successfully completed the placebo lead-in phase (Period A) and met the following criteria continued into the double-blind phase of the study. Laboratory criteria were obtained from the Visit 1 (Day 1) analysis K AER of 20-700 mg/min in two-timed overnight urine collections performed on Day 12 and 13. Both collections had to meet the AER criteria to be eligible for randomization into the double-blind phase of the study K Systolic blood pressure X150 mm Hg and/or a diastolic blood pressure X95 mm Hg K Subjects continuing to meet the overall inclusion criteria and no exclusion criteria (including laboratory criteria) for the study Abbreviations: ACE-I, angiotensin-converting enzyme inhibitor; AER, albumin excretion rate; CAD, coronary artery disease; CVA, cerebrovascular accident; MI, myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; NYHA, New York Heart Association; PVD, peripheral vascular disease.
Urine samples will be collected overnight and the results displayed in mg/min and mg/g creatinine. An overnight sampling protocol was chosen to enable the results to be compared readily with other studies that used an overnight protocol, such as IRMA-2. 22 Samples will be cooled on the morning of collection and shipped to a central measurement facility to ensure consistency of analysis. Albumin concentrations will be determined using an immunoturbidometric assay (TINA quant albumin, Roche Diagnostics GmbH, Basel, Switzerland). Albumin samples are stable at room temperature for 7 days using this method.
Statistical methods
Data will be summarized with respect to demographic and baseline characteristics, efficacy and safety measurements. The primary efficacy analysis will be performed in all randomized subjects excluding those whose baseline urinary AER was below 20 mg/min when averaged over the two baseline measurements. The safety analysis will be performed in all patients who received at least one dose of double-blind study medication.
Urinary albumin measurements for each subject at baseline and week 20 will both be the arithmetic mean of two measurements. For the primary efficacy analysis, these will be converted into their natural logarithms and changes from baseline calculated using a natural logarithmic scale.
An analysis of covariance will be used to compare the response between the two treatment groups, with baseline assessment as covariate, and treatment as the main effect in the model. The typical sample sizes at individual sites are expected to be small enough to preclude the use of study site as an additional term in the model. The covariateadjusted difference between the treatment groups will be tested using a two-sided approach, employing a significance level of 0.05.
Mean AER values at baseline and on therapy, mean changes and adjusted mean changes will be converted back from logs to the raw scale using the exponential transformation to yield geometric means and mean ratios. The between-group logarithmic difference and its 95% confidence limit will also be converted back to the scale of ratios. AER changes will also be summarized descriptively by carrying forward the last double-blind value for subjects without a measurement at week 20.
Subgroup analyses will be conducted with respect to the primary efficacy variable for microalbuminuric subjects (AERo200 mg/min) and overt nephropathic subjects (4200 mg/min) and the presence or absence of type II diabetes. As with the principle treatment groups, a 95% confidence interval for mean AER change from baseline will be provided for all subgroup categories. Additionally, mean changes from baseline in trough blood pressure and heart rates will be presented for each treatment group and visit.
Sample size
The IMPROVE study requires a sample size of 200 subjects randomized to each group, in order to provide at least 80% power to detect a 20% reduction in the geometric mean ratio for irbesartan relative to placebo. This planned sample size includes allowance for a 10% dropout rate, and assumes a standard deviation of 0.73 natural logarithm units for the logarithmically transformed Study to evaluate management of proteinuria GL Bakris et al ratio of post to baseline AER, and two-sided testing at an alpha level of 0.05 for primary analysis.
Discussion
Most patients at high cardiovascular risk with hypertension and proteinuria or microalbuminuria will need a combination of two or more antihypertensive drugs to achieve appropriate blood pressure control. Diuretics are commonly added to ACE inhibitor or ARB monotherapy and potentiate the antihypertensive capacity of RAAS-directed drugs; the same potentiation of blood pressure lowering is seen when non dihydropyridine calcium antagonists are combined with either an ACE inhibitor or an ARB. 27, 28 This greater blood pressure control facilitates a further decrease in albumin excretion and has been shown to reduce the risk of new onset microalbuminuria in normoalbuminuric patients. 29 The IMPROVE trial has been designed to establish whether combined ACE inhibitor and ARB therapy does indeed provide greater albuminuria control as compared to RAAS blockade with ACE inhibitors alone in the setting of a substantial randomized trial. Specifically, the trial will determine whether the combined use of irbesartan and ramipril is more effective than ramipril alone in reducing AER in hypertensive patients with a high global cardiovascular risk and albuminuria. Provided that similar blood pressure control is achieved in both groups, any differences that emerge with regard to albumin control are likely to reflect differences in the therapeutic model of RAAS blockade that are independent of blood pressure control. By continuing active treatment for a relatively long period of 20 weeks, it is anticipated that the IMPROVE study will capture any continuing divergence in the response in the mono-and dual therapy treatment arms, as was observed in the COOPERATE study. 25 The importance of the IMPROVE trial is underlined by the close correlation between albuminuria and cardiovascular outcomes observed in hypertensive patients in the LIFE and HOPE studies. 20, 30 Should the combination of ramipril and irbesartan investigated in the IMPROVE trial succeed in further diminishing urinary albumin excretion compared with ramipril alone, improved long-term cardiovascular and kidney outcomes could be expected in these patients. Ongoing studies, notably the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) study, 31 will be necessary to establish definitive outcomes data for the combined use of ARBs and ACE inhibitors, but the results of the IMPROVE trial will aid the development of this emerging therapeutic concept. It is anticipated that the results of the completed study will be published in early 2007.
